Medtronic Annual Analyst Meeting In Brief
This article was originally published in The Gray Sheet
"Paranoid" but not "paralyzed": The recent spate of Guidant recalls is not causing a "material dampening effect on the marketplace," Cardiac Rhythm Management President Steve Mahle said Oct. 11 at the firm's annual analyst meeting in Minneapolis, though he admitted that "anytime your business becomes a front page article repeatedly in the newspapers is usually not good." Mahle, who stressed Medtronic's work with AdvaMed to help determine when firms should notify patients and physicians of potential problems with their medical devices, said that the "biggest issue we have to deal with...is putting things into perspective." He added: "Survivors have to be paranoid. We're sufficiently paranoid, but we're not paranoid where we're paralyzed in terms of doing what's right for the business"...
You may also be interested in...
Japan's regulatory and reimbursement systems came under fire this week from lawmakers on Capitol Hill and attendees of AdvaMed's international conference in Arlington, Va
Medtronic's argument that the Restore rechargeable implantable neurostimulator represents a substantial clinical improvement over existing devices convinced CMS to award the device new technology add-on payment for fiscal year 2007
Medtronic's recent boost in intellectual property protection resources could increase the likelihood of infringement prosecutions against competitors in the near future